NIKKEI 225
28,942.14 -280.63 (-0.96%) HANG SENG
19,763.91 -158.54 (-0.80%) CRUDE OIL
90.78 +0.28 (+0.31%) GOLD FUTURES
1,771.90 +0.70 (+0.04%) DOW
33,999.04 +18.72 (+0.06%) BTC-GBP
19,428.11 -267.27 (-1.36%)
Novacyt S.A. (NCYT.L)
| Previous close | 110.50 |
| Open | 108.75 |
| Bid | 108.50 x 0 |
| Ask | 109.15 x 0 |
| Day's range | 108.61 - 112.10 |
| 52-week range | 1.32 - 497.30 |
| Volume | |
| Avg. volume | 226,441 |
| Market cap | 78.212M |
| Beta (5Y monthly) | -2.71 |
| PE ratio (TTM) | 0.92 |
| EPS (TTM) | 119.80 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Launch of Novacyt’s first fully lyophilised PROmate® assays
PARIS & CAMBERLEY, England, August 04, 2022--Regulatory News: Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT) ("Novacyt", the "Company" or the "Group"), an international specialist in clinical diagnostics, announces the launch of the Company’s first fully lyophilised (freeze-dried), direct-to-PCR assays. This new class of PROmate® assay enables shipping and transportation at ambient temperatures to remote regions or in areas without a centralised cold storage supply chain, providing an extended glob
- Business Wire
Novacyt S.A. ("Novacyt", the "Company" or the "Group"): Launch of Research-Use-Only Adenovirus F41 Assay
PARIS & CAMBERLEY, England, July 28, 2022--Regulatory News: Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces the launch of a research-use-only (RUO) polymerase chain reaction (PCR) assay for the detection of adenovirus F41, in response to recent cases of acute hepatitis in children. This launch expands Novacyt’s genesig® real-time PCR diagnostic product portfolio and is in line with the Company’s strategy to maintain its position as a gl
- Business Wire
Novacyt S.A. ("Novacyt", the "Company" or the "Group"): Approval of exsig™ COVID-19 Direct Test in the UK Under CTDA Legislation
PARIS & CAMBERLEY, England, July 15, 2022--Regulatory News: Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company’s exsig™ COVID-19 Direct Real-Time PCR test has been approved in the UK under the UK Health Security Agency's Medical Devices (Coronavirus Test Device Approvals) (Amendment) Regulations 2021 ("CTDA").
